BRIEF published on 11/13/2025 at 07:35, 2 months 16 days ago Dermapharm maintient sa stabilité malgré les ajustements de son portefeuille Croissance Et Bénéfices Dermapharm Restructuration Du Portefeuille Résultats Financiers De 2025 Médicaments De Marque
BRIEF published on 11/13/2025 at 07:35, 2 months 16 days ago Dermapharm Maintains Stability Amid Portfolio Adjustments Growth And Earnings Branded Pharmaceuticals Dermapharm 2025 Financial Results Portfolio Restructuring
PRESS RELEASE published on 11/13/2025 at 07:30, 2 months 16 days ago Stable earnings despite portfolio adjustment - 2025 guidance confirmed, strong growth in branded pharmaceuticals Dermapharm Holding SE reports stable earnings despite portfolio adjustments in Q3 2025, confirms 2025 guidance and strong growth in branded pharmaceuticals Pharmaceuticals Growth Earnings Dermapharm Holding SE Portfolio Adjustment
BRIEF published on 08/26/2025 at 07:35, 5 months 3 days ago Dermapharm annonce une activité stable au premier semestre 2025 et une croissance de l'EBITDA au deuxième trimestre Résultats Financiers Croissance De L'EBITDA Stabilité Des Revenus Produits Pharmaceutiques De Marque Performances De Dermapharm
BRIEF published on 08/26/2025 at 07:35, 5 months 3 days ago Dermapharm Reports Stable Business in H1 2025 and Q2 EBITDA Growth Financial Results EBITDA Growth Revenue Stability Branded Pharmaceuticals Dermapharm Performance
PRESS RELEASE published on 08/26/2025 at 07:30, 5 months 3 days ago Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter Dermapharm confirms stable business development in H1 2025 with EBITDA growth in Q2. Full-year guidance for 2025 reiterated. Branded pharmaceuticals main growth driver Revenue Pharmaceuticals EBITDA Growth Dermapharm H1 2025
BRIEF published on 08/12/2025 at 07:35, 5 months 17 days ago Dermapharm Holding SE poursuit sa croissance au deuxième trimestre 2025 Prévisions De Revenus Croissance De L'EBITDA Produits Pharmaceutiques De Marque Dermapharm Performances Du Deuxième Trimestre 2025
BRIEF published on 08/12/2025 at 07:35, 5 months 17 days ago Dermapharm Holding SE Continues Growth in Q2 2025 Revenue Forecast EBITDA Growth Branded Pharmaceuticals Dermapharm Q2 2025 Performance
PRESS RELEASE published on 08/12/2025 at 07:30, 5 months 17 days ago Dermapharm Holding SE remains on projected growth trajectory in Q2 2025 Dermapharm Holding SE reports Q2 2025 results in line with expectations. Confirms full-year guidance of EUR 1,160–1,200 million revenue and EUR 322–332 million EBITDA Pharmaceuticals EBITDA Growth Dermapharm Holding SE Full-year Guidance Q2 2025 Results
BRIEF published on 06/26/2025 at 17:48, 7 months 3 days ago Dermapharm Holding SE Approves EUR 0.90 Dividend Per Share Sustainability Dividend AGM Financial Outlook Dermapharm
Published on 01/30/2026 at 00:00, 1 hour 4 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 2 hours 4 minutes ago PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A
Published on 01/29/2026 at 18:45, 6 hours 19 minutes ago Silver Spruce Appoints Vice-President of Exploration
Published on 01/29/2026 at 18:00, 7 hours 4 minutes ago PPX Mining Announces Grant of Restricted Share Units and Deferred Share Units
Published on 01/29/2026 at 17:00, 8 hours 4 minutes ago Sparta Reports on Delay in Filing Annual Financial Statements
Published on 01/30/2026 at 00:07, 56 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appointment of independent non-executive director
Published on 01/29/2026 at 21:02, 4 hours 1 minute ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/29/2026 at 20:59, 4 hours 4 minutes ago Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited
Published on 01/29/2026 at 20:57, 4 hours 6 minutes ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 01/29/2026 at 18:30, 6 hours 34 minutes ago ALPOU - Groupe POULAILLON chiffre d'affaires trimestriel T1 2025-2026 et Focus sur les activités
Published on 01/29/2026 at 18:00, 7 hours 4 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 18:00, 7 hours 4 minutes ago GUILLEMOT CORPORATION : CHIFFRE D’AFFAIRES CONSOLIDE ANNUEL 2025 : +2%
Published on 01/29/2026 at 17:45, 7 hours 19 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
